OClawVPS.com
Colossal Biosciences
Edit

Colossal Biosciences

https://colossal.com/
Last activity: 07.04.2026
Active
Categories: AIAvianBioengineeringBiotechnologyConservationDeepTechDeExtinctionDe-extinctionGeneticEngineeringGeneticsGenomics
The science of genetics. The business of discovery.

Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.
Likes
248
Followers
4.91K
Followers
3.36K
Website visits
21.5K /mo.
Mentions
106
Location: United States
Employees: 51-200
Total raised: $805M
Valuation: $10.32B
Founded date: 2021

Investors 10

Funding Rounds 6

DateSeriesAmountInvestors
10.11.2025Series C$320MARCH Ventu...
17.01.2025Series C$200M-
02.02.2023Series B$150MPEAK6 Inve...
17.01.2023Series A$60M-
09.03.2022Series A$60M-
13.09.2021-$15M-

Mentions in press and media 106

DateTitleDescription
07.04.2026HexemBio Raises $10.4M in Seed FundingHexemBio, a NYC-based biotechnology company developing blood stem cell rejuvenation therapies, raised $10.4M in Seed funding. The round was led by Draper Associates with participation from SOSV, Seraphim, and other investors. The company in...
10.11.2025Inside Colossal Biosciences: Interview with CEO & Co-Founder Ben LammColossal Biosciences is a company leading the field of de-extinction and advanced genetic engineering. Utilizing a sophisticated platform built on CRISPR technology, synthetic biology, and artificial intelligence, Colossal’s primary goal is...
29.09.2025Future-Proofing Biodiversity: Colossal's Strategy to Preserve What Can't Be ReplacedCreated by Carl Williams Published: Sep 29 2025, 22:52 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
22.09.2025Colossal Biosciences: $120 Million Raised At $10.32 Billion Valuation For Advancing Dodo De-ExtinctionColossal Biosciences, a leading company focused on the de-extinction of species, has made significant strides in the field of avian cellular science. Recently, they announced an exciting development that brings us closer to the revival of t...
22.09.2025Colossal Biosciences Raises $120 Million at a $10.32 Billion Valuation Only paid subscribers can comment on this postColossal Biosciences is a de-extinction company focused on leveraging advances in genetic engineering and reproductive technologies to bring back extinct species, with a current focus on the Dodo and the Moa. Its mission also extends to adv...
19.09.2025De-Extinction Dawn: Colossal Biosciences Secures Massive Capital for Species RevivalColossal Biosciences, a leading de-extinction biotech firm, recently secured an additional $120 million. This significant investment boosts their Series C funding to $320 million, bringing total capital raised to an impressive $555 million....
18.09.2025Colossal Biosciences Raises Additional $120M in FundingColossal Biosciences, a Dallas, TX-based de-extinction company, raised $120M in new funding adding to its $200M Series C, bringing this round of capital to $320M. Backers included from USIT, Bob Nelsen, and Peter Jackson. The company intend...
18.09.2025Стартап Colossal Biosciences привлек $120 млн на воскрешение птицы додоБиотехнологический стартап Colossal Biosciences, занимающийся воскрешением вымерших животных, привлек $120 млн. Об этом сообщает Bloomberg. По словам гендиректора компании Бена Лэмма, Colossal сможет возродить птицу додо (дронта) через пять...
15.09.2025Flagship's Lila Sciences lands $235M to expand AI-powered autonomous research labsFlagship Pioneering’s Lila Sciences has landed a substantial $235 million series A as it looks to exceed the current limits of the drug discovery process through automation. The round, which more than doubles the AI outfit’s March debut of ...
01.09.2025Ben Lamm Teams with George Church for $30M AI Company AstromechBen Lamm has partnered with Harvard researcher George Church to establish Astromech, a new artificial intelligence company that has raised $30 million, according to SEC filings. Their collaboration builds on an existing relationship forged ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In